Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Alector

AstraZeneca AZ

AZ hopes dosing will differentiate its severe asthma therapy

Plans to file benralizumab in EU and US by the end of the year spurred by phase III data

- PMLiVE

Alzheimer’s disease: reviewing the immediate treatment horizon

Account Manager Stuart Goodman takes a look at some of the promising categories of Phase 3 treatments that could soon be available to patients with Alzheimer's disease.

Blue Latitude Health

- PMLiVE

Vectura’s Flutiform flunks phase III COPD test

But new AirFluSal data demonstrates superior patient adherence over GSK’s Seretide/Advair

- PMLiVE

Teva gets EU nod for severe asthma drug Cinqaero

Once-monthly dose able to improve asthma control

Biogen Idec building

Eisai and Biogen plan phase III trials for Alzheimer’s drug

BACE inhibitor E2609 may offer new treatment option

- PMLiVE

Boehringer starts to feel impact of Spiriva generics

Asthma and COPD therapy facing increasing competition in ‘crowded’ market category

- PMLiVE

Pfizer buys gene therapy specialist Bamboo

Expands pipeline with Duchenne muscular dystrophy candidate in deal worth $700m

- PMLiVE

GSK and Google launch bioelectronics venture

Will develop electronic implants to treat chronic diseases, including diabetes

- PMLiVE

New drugs breathe life into GSK’s respiratory business

Revlar/Breo and Anoro offset ongoing Seretide decline with new sales growth

- PMLiVE

Tau protein drug fails late-stage trial

Alzheimer’s disease therapy only showed benefit in patients with no existing treatments

Brextinction

Evolution predicts tragic consequences from the UK's choice

- PMLiVE

FCB Health takes home network prize at the Creative Floor Awards

And GSK wins Best Healthcare Company at advertising ceremony

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links